Piotr J. Wysocki - Publications, H-index & Citations

Piotr J. Wysocki

jagiellonian university medical college

27H指数

298论文数

2.7K被引数

收录论文 62

发表时间

Clinical Decision-Making After Receptor Conversion Following Neoadjuvant Therapy in Breast Cancer: A Three-Strategy Framework 新辅助治疗后乳腺癌受体转换后的临床决策制定：一种三策略框架

Journal of Clinical Medicine

IF2.9

2026-09-16

OAAI

Katarzyna Pogoda; Magdalena Czopowicz; Wojciech Olszewski; Monika Durzynska; Piotr Jan Wysocki

Adverse Events as a Surrogate of Sufficient Pharmacological Exposure in Metronomic Combination Chemotherapy: Extended Real-World Cohort Analysis of the FulVEC Regimen in Metastatic ER+/HER2− Breast Cancer

Cancers

IF4.4

2026-08-18

OAAI

Anna Buda-Nowak; Maciej Lubaś; Michał Jurczyk; Łukasz Kwinta; Anna Michałowska-Kaczmarczyk; Agnieszka Przywara-Sikora; Kamil Konopka; Maciej Koniewski; Joanna Kadłuczka; Olga Szczerbak; Piotr J. Wysocki

Healthcare costs associated with renal cell carcinoma recurrence following curative surgery: a real-world national claims data analysis from Poland 波兰全国医保索赔数据真实世界分析：根治性手术治疗后肾细胞癌复发的相关医疗费用

BMC Health Services Research

IF3

2026-08-08

OAAI

Maciej Niewada; Ewa Chudzyńska; Tomasz Macioch; Anna Staniszewska; Beata Koń; Dawid Grzeszczuk; Daniel Szulczyk; Piotr J. Wysocki; Bożena Cybulska-Stopa

Predictive Biomarkers of Metronomic Chemotherapy Response in Solid Tumors: Chasing an Elusive Signal 实体瘤中低剂量密集化疗反应的预测性生物标志物：追寻一个难以捉摸的信号

Cancers

IF4.4

2026-08-04

OAAI

Piotr Jan Wysocki; Łukasz Kwinta; Ewa Wysocka

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial 一线durvalumab联合曲妥珠单抗deruxtecan治疗局部晚期不可切除或转移性，激素受体阴性，HER2-low乳腺癌的女性: 多中心，开放标签，1b/2期海棠平台试验

Nature Cancer

IF28.5

2026-06-08

OAAI

Peter Schmid; Seock-Ah Im; Zbigniew Nowecki; Piotr J. Wysocki; Jacek Jassem; Kyung Hae Jung; Simon Lord; Jon Armstrong; Ross Stewart; Petra Vuković; Neelima Denduluri; Yeon Hee Park

Post-Chemotherapy Antibody-Based Continuation and Maintenance Strategies in HER2-Positive Metastatic Breast Cancer: A Translational Narrative Review 化疗后抗体为基础的持续治疗与维持策略在HER2阳性转移性乳腺癌中的应用：一项转化叙事性综述

Antibodies

IF2.7

2026-04-16

OAAI

Katarzyna Pogoda; Karolina Lewińska; Paulina Kalman; Anna Bałata; Piotr J. Wysocki

Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review HER2阳性早期乳腺癌患者疾病复发的风险因素及对治疗的启示：一篇叙事性综述

Oncology and Therapy

IF3.2

2025-11-08

OAAI

Marina E. Cazzaniga; Luis Costa; Gilles Freyer; Joseph Gligorov; Henrik Lindman; Piotr J. Wysocki; Rupert Bartsch

Correlation Between Urinary Osteopontin Concentration and the Mineral Content and Composition of Kidney Stones 尿骨桥蛋白浓度与肾结石矿物质含量及组成的相关性

Journal of Clinical Medicine 2025, Vol. 14, Page 6247

IF2.9

2025-09-05

OAAI

Maciej Jaromin; Piotr Kutwin; Tomasz Konecki; Hanna Jerczyńska; Piotr Wysocki; Magdalena Gajek; Waldemar Maniukiewicz; Małgorzata Iwona Szynkowska-Józwik; Dariusz Moczulski

Elevated Zinc and Potassium Levels in Renal Calculi Indicate Distinct Pathophysiological Mechanisms in Urolithiasis 肾结石中升高的锌和钾水平表明尿石症存在不同的病理生理机制

pathophysiology

IF0

2025-08-17

OAAI

Maciej Jaromin; Marcin Cichocki; Tomasz Konecki; Piotr Kutwin; Waldemar Maniukiewicz; Piotr Wysocki; Magdalena Gajek; Małgorzata Iwona Szynkowska-Jóźwik; Dariusz Moczulski

Elemental composition of bee products from diverse botanical sources: Implications for consumer safety 来自不同植物来源的蜂产品元素组成：对消费者安全的启示

Journal of Food Composition and Analysis

IF4.6

2025-07-17

OAAI

Magdalena Gajek; Piotr Wysocki; Katarzyna Mordaka; Małgorzata Iwona Szynkowska Jóźwik

Ectopic Cushing's Syndrome in Advanced Small-Cell Lung Cancer (SCLC): Clinical Challenges and Therapeutic Insights 异位库欣综合征在晚期小细胞肺癌（SCLC）中的临床挑战和治疗见解

CANCERS

IF4.4

2025-05-09

OAAI

Gamrat-Zmuda, Aleksandra; Minasyan, Mari; Wysocki, Piotr J.; Hubalewska-Dydejczyk, Alicja; Gilis-Januszewska, Aleksandra

Complete remission of hypercortisolemia in a patient with severe ectopic Cushing syndrome caused by small-cell lung cancer

POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ

IF4.7

2024-05-29

OAAI

Gamrat, Aleksandra; Rzepka, Ewelina; Ciszek, Karol; Wysocki, Piotr J.; Hubalewska-Dydejczyk, Alicja; Gilis-Januszewska, Aleksandra

Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice

FRONTIERS IN ONCOLOGY

IF3.3

2024-01-23

OAAI

Knetki-Wroblewska, Magdalena; Dziadziuszko, Rafal; Jankowski, Tomasz; Krawczyk, Pawel; Bryl, Maciej; Stencel, Katarzyna; Wrona, Anna; Bandura, Artur; Smok-Kalwat, Jolanta; Rok-Knapinska, Jolanta; Szydziak-Zwierzynska, Kinga; Rogoziewicz, Krzysztof; Czyzewicz, Grzegorz; Wojtowicz, Monika; Wojtukiewicz, Marek; Kalinka, Ewa; Wysocki, Piotr J.; Lobacz, Mateusz; Milanowski, Janusz; Pawlik, Hubert; Kowalski, Dariusz M.; Krzakowski, Maciej

Datopotamab deruxtecan (Dato-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Schmid, P.; Wysocki, P. J.; Ma, C. X.; Park, H.; Fernandes, R.; Lord, S.; Baird, R. D.; Prady, C.; Jung, K. H.; Asselah, J.; Huisden, R.; Stewart, R.; Heider, K.; Vukovic, P.; Denduluri, N.; Nowecki, Z.

Immunogenicity and safety of SARS-CoV-2 recombinant protein nanoparticle vaccine GBP510 adjuvanted with AS03 interim results of a randomised, active-controlled, observer-blinded, phase 3 trial 以AS03为佐剂的SARS-CoV-2重组蛋白纳米颗粒疫苗GBP510的免疫原性和安全性随机，主动对照，观察者盲，3期试验的中期结果

ECLINICALMEDICINE

IF10

2023-10-01

OAAI

Song, Joon Young; Choi, Won Suk; Heo, Jung Yeon; Kim, Eun Jin; Lee, Jin Soo; Jung, Dong Sik; Kim, Shin -Woo; Park, Kyung-Hwa; Eom, Joong Sik; Jeong, Su Jin; Lee, Jacob; Kwon, Ki Tae; Choi, Hee Jung; Sohn, Jang Wook; Kim, Young Keun; Yoo, Byung Wook; Jang, In-Jin; Capeding, Maria Z.; Roman, Francois; Breuer, Thomas; Wysocki, Piotr; Carter, Lauren; Sahastrabuddhe, Sushant; Song, Manki; D'Cor, Naveena; Kim, Hun; Ryu, Ji Hwa; Lee, Su Jeen; Park, Yong Wook; Cheng, Hee Jin

Removal of soluble TNF receptors as a novel form of immunotherapy for patients with advanced solid tumors

CANCER RESEARCH

IF16.6

2023-04-04

PREAI

Wysocki, Piotr J.; Tomczak, Piotr; Jankowski, Tomasz; Nowikiewicz, Tomasz; Markel, Gal; Shapira, Ronnie; Demir, Gokhan; Bozkurt, Mustafa; Bilgrami, Sameera; Marleau, Annette; Ostrowski, Adam; Florin, Lawrence; Manax, Victoria; Segal, Robert

Metronomic chemo-endocrine treatment (FulVEC) for patients with advanced hormone-refractory ER plus breast cancer

CANCER RESEARCH

IF16.6

2023-03-01

PREAI

Buda-Nowak, Anna; Kwinta, Lukasz; Potocki, Pawel; Streb, Joanna; Wysocki, Piotr

Trastuzumab deruxtecan (T-DXd) plus durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR-), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study

CANCER RESEARCH

IF16.6

2023-03-01

PREAI

Schmid, Peter; Wysocki, Piotr; Park, Yeon H.; Jassem, Jacek; Jung, Kyung Hae; Lord, Simon; Huisden, Robert; Stewart, Ross; Vukovic, Petra; Nunes, Ana T.; Nowecki, Zbigniew

CANCER RESEARCH

IF16.6

2023-03-01

OAAI

Schmid, Peter; Wysocki, Piotr; Ma, Cynthia; Park, Yeon H.; Fernandes, Ricardo; Lord, Simon; Baird, Richard D.; Prady, Catherine; Jung, Kyung Hae; Asselah, Jamil; Huisden, Robert; Stewart, Ross; Vukovic, Petra; Nunes, Ana T.; Nowecki, Zbigniew

Metronomic Chemo-Endocrine Therapy (FulVEC) as a Salvage Treatment for Patients with Advanced, Treatment-Refractory ER+/HER2-Breast Cancer-A Retrospective Analysis of Consecutive Patients Data 节律性化学内分泌疗法 (FulVEC) 作为晚期，难治性ER /HER2-Breast患者的挽救性治疗-连续患者数据的回顾性分析

JOURNAL OF CLINICAL MEDICINE

IF2.9

2023-02-08

OAAI

Buda-Nowak, Anna; Kwinta, Lukasz; Potocki, Pawel; Michalowska-Kaczmarczyk, Anna; Slowik, Agnieszka; Konopka, Kamil; Streb, Joanna; Koniewski, Maciej; Wysocki, Piotr J. J.

研究方向